Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q4 FY25 results · Jan–Mar 2025
Glenmark Pharmaceuticals reported revenue from operations of ₹3,256.21 crore (up 6.3% from Q4 FY24) and net profit of ₹4.38 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,256.21 | 3,062.95 | +6.3% | 3,387.55 | −3.9% |
| Other income | 11.69 | 773.16 | −98.5% | 31.13 | −62.5% |
| Total income | 3,267.89 | 3,836.12 | −14.8% | 3,418.68 | −4.4% |
| Profit before tax | 7.97 | 530.83 | −98.5% | 456.33 | −98.3% |
| Net profit for the period | 4.38 | (1,214.27) | Turned profit | 348.03 | −98.7% |
| Attributable to shareholders of the company | 4.65 | (1,218.28) | Turned profit | — | — |
| EPS, basic (₹) | 0.16 | (43.18) | Turned profit | 12.33 | −98.7% |
| Net margin (%) | 0.1 | -39.6 | 10.3 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,009.49 | 2,148.22 | −6.5% | 2,251.28 | −10.7% |
| Other income | 88.45 | 786.27 | −88.8% | 129.19 | −31.5% |
| Total income | 2,097.95 | 2,934.49 | −28.5% | 2,380.47 | −11.9% |
| Profit before tax | 181.16 | 6,294.85 | −97.1% | 559.49 | −67.6% |
| Net profit for the period | 147.76 | 4,613.69 | −96.8% | 413.80 | −64.3% |
| EPS, basic (₹) | 5.24 | 163.50 | −96.8% | 14.66 | −64.3% |
| Net margin (%) | 7.4 | 214.8 | 18.4 |
Consolidated
- Filed with BSE
- 23 May 2025, 23:04 IST
- Board meeting
- 23 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 May 2025, 23:04 IST
- Board meeting
- 23 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE